These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31025833)

  • 1. Removal Characteristics of Immunoadsorption with the Tryptophan-Immobilized Column Using Conventional and Selective Plasma Separators in the Treatment of Myasthenia Gravis.
    Ohkubo A; Okado T; Sakurasawa T; Maeda T; Itagaki A; Yamamoto H; Miyamoto S; Seshima H; Kurashima N; Mori T; Iimori S; Sohara E; Rai T; Uchida S; Naito S
    Ther Apher Dial; 2019 Jun; 23(3):271-278. PubMed ID: 31025833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal volume of processed plasma and total number of selective plasmapheresis sessions in the treatment of patients with severe generalized myasthenia gravis.
    Yeh JH; Chiu HC
    J Clin Apher; 1999; 14(4):177-80. PubMed ID: 10611627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis.
    Yeh JH; Chiu HC
    J Neurol; 2000 Jul; 247(7):510-3. PubMed ID: 10993491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunoadsorption therapy for myasthenia gravis: study on the adsorption capacity of an immunoadsorption column].
    Yeh JH; Chiu HC
    J Microbiol Immunol Infect; 1999 Jun; 32(2):121-5. PubMed ID: 11565565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Removal Characteristics of Immunoadsorption With the Immusorba TR-350 Column Using Conventional and Selective Plasma Separators.
    Ohkubo A; Okado T; Miyamoto S; Goto K; Yamamoto M; Maeda T; Itagaki A; Seshima H; Kurashima N; Sohara E; Uchida S; Rai T
    Ther Apher Dial; 2016 Aug; 20(4):360-7. PubMed ID: 27523076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis.
    Köhler W; Bucka C; Klingel R
    J Clin Apher; 2011 Dec; 26(6):347-55. PubMed ID: 22095647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semi-selective immunoadsorption treatment in myasthenia gravis.
    Splendiani G; Passalacqua S; Barbera G; Sturniolo G; Costanzi S; Fulignati P; Casciani CU
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(5):1145-51. PubMed ID: 1457688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term treatment of refractory myasthenia gravis with immunoadsorption].
    Wagner S; Janzen RW; Mohs C; Pohlmann S; Klingel R; Grützmacher PW
    Dtsch Med Wochenschr; 2008 Nov; 133(46):2377-82. PubMed ID: 18988129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In-vitro and in-vivo studies on the selective immunoadsorption treatment of neurological diseases].
    Heininger K
    Schriftenr Neurol; 1993; 33():1-91. PubMed ID: 8327864
    [No Abstract]   [Full Text] [Related]  

  • 10. Removal of antiacetylcholine receptor antibodies by protein-A immunoadsorption in myasthenia gravis.
    Berta E; Confalonieri P; Simoncini O; Bernardi G; Busnach G; Mantegazza R; Cornelio F; Antozzi C
    Int J Artif Organs; 1994 Nov; 17(11):603-8. PubMed ID: 7744521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoadsorption With a Tryptophan-Immobilized Column Using Conventional and Selective Plasma Separators in the Treatment of Myasthenia Gravis.
    Ohkubo A; Kurashima N; Okado T
    Ther Apher Dial; 2018 Jun; 22(3):301-302. PubMed ID: 29781125
    [No Abstract]   [Full Text] [Related]  

  • 12. Antigen-specific immunoadsorption of anti-acetylcholine receptor antibodies from sera of patients with myastenia gravis.
    Sun C; Meng F; Li Y; Jin Q; Li H; Li F
    Artif Cells Blood Substit Immobil Biotechnol; 2010 Apr; 38(2):99-102. PubMed ID: 20196680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma exchange with selective immunoadsorption of anti-acetylcholine receptor antibodies.
    Somnier FE; Langvad E
    J Neuroimmunol; 1989 Apr; 22(2):123-7. PubMed ID: 2647782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, stability, and effectiveness of immunoadsorption under membrane plasmapheresis treatment for myasthenia gravis.
    Hosokawa S; Oyamaguchi A
    ASAIO Trans; 1990; 36(3):M207-8. PubMed ID: 2252658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis.
    Liu JF; Wang WX; Xue J; Zhao CB; You HZ; Lu JH; Gu Y
    Ther Apher Dial; 2010 Apr; 14(2):153-60. PubMed ID: 20438536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoadsorption in Guillain-Barré syndrome and myasthenia gravis.
    Haupt WF; Rosenow F; van der Ven C; Birkmann C
    Ther Apher; 2000 Jun; 4(3):195-7. PubMed ID: 10910018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The six year experience of plasmapheresis in patients with myasthenia gravis.
    Chiu HC; Chen WH; Yeh JH
    Ther Apher; 2000 Aug; 4(4):291-5. PubMed ID: 10975476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Plasmapheresis in patients with myasthenia gravis].
    Konishi T
    Nihon Rinsho; 2008 Jun; 66(6):1165-71. PubMed ID: 18540364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Substance Removal by Immunoadsorption With a Selective Plasma Separator.
    Hanafusa N; Yamamoto H; Tamachi M; Torato T; Sakurai S; Tsuchiya K; Nitta K; Nangaku M
    Ther Apher Dial; 2017 Jun; 21(3):218-225. PubMed ID: 28661087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoadsorption therapy for myasthenia gravis.
    Shibuya N; Sato T; Osame M; Takegami T; Doi S; Kawanami S
    J Neurol Neurosurg Psychiatry; 1994 May; 57(5):578-81. PubMed ID: 8201327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.